Showing 1,281 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

IAS 2021: Injectable treatment for multidrug-resistant HIV Video

July 2021
Injectable & long-acting HIV treatment

IAS 2021: Injectable lenacapavir for people starting HIV treatment Video

July 2021
New & experimental HIV treatments

HIV: Could Another Two-Drug Regimen Be on the Horizon?

Editor's pick
Medscape (requires free registration)
21 July 2021
Injectable & long-acting HIV treatment

Twice-a-year injected drug shows promise for first-line HIV treatment

News
19 July 2021
New & experimental HIV treatments

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy

News
17 July 2021
Pharmaceutical industry

Gilead files long-acting HIV med for patients running out of options

Editor's pick
FierceBiotech
1 July 2021
Pharmaceutical industry

GSK puts long-acting injectables at heart of HIV growth plans, downplays threat of oral rival from Gilead and Merck

Editor's pick
FiercePharma
29 June 2021
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options

Editor's pick
Gilead press release
29 June 2021
Injectable & long-acting HIV treatment

Top 5 stories on injectable HIV treatment and prevention from CROI 2021

News
23 March 2021
Injectable & long-acting HIV treatment

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Editor's pick
Gilead press release
15 March 2021
Injectable & long-acting HIV treatment

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years

News
12 March 2021
New & experimental HIV treatments

HIV capsid inhibitor offers new option for people with highly resistant HIV

News
10 March 2021
New & experimental HIV treatments

ViiV Healthcare receives Marketing Authorisation for Rukobia (fostemsavir), a first-in-class attachment inhibitor in combination with other antiretrovirals for the treatment of adults with multidrug-resistant HIV

Editor's pick
ViiV Healthcare press release
8 February 2021
Antibody-based prevention

Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’

News
27 January 2021
Injectable & long-acting HIV treatment

FDA approves first long-acting injectable to treat HIV infection

Editor's pick
STAT
22 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Editor's pick
ViiV Healthcare press release
22 January 2021
People & personal stories

Anthony Fauci: “I don’t do this because I’m a hero. I do it because it’s necessary.”

News
14 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

Editor's pick
ViiV Healthcare press release
21 December 2020
New & experimental HIV treatments

ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Editor's pick
ViiV Healthcare press release
11 December 2020
HIV treatment

Top 10 HIV Clinical Developments of 2020

Editor's pick
TheBodyPro
1 December 2020
Global health initiatives

aidsmapLIVE: World AIDS Day 2020 special Video

November 2020
New & experimental HIV treatments

Data sets up 2021 filings for Gilead's twice-a-year HIV drug lenacapavir

Editor's pick
Pharmaphorum
20 November 2020
New & experimental HIV treatments

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Editor's pick
Gilead press release
20 November 2020
Injectable & long-acting HIV treatment

Long-acting injectables appear feasible for long-term HIV treatment

News
4 November 2020